东盟医疗器械指令（AMDD）在柬埔寨的适用方式与边界

1. Key Takeaway

The ASEAN Medical Device Directive (AMDD) is the technical layer of Cambodia’s device rules, but it is not a provision of Cambodian domestic law. The AMDD was signed by the 10 ASEAN member states, and its Article 22 states expressly that the Directive enters into force on 1 January 2015 and is valid only among the member states that have ratified or accepted it.

For Cambodia, the AMDD provides four bodies of technical content: definitions and scope, the four-class classification rules, the common technical document template (CSDT, Annex 4), and the post-market alert system (PMAS, Article 12). These give the Cambodian rule system its skeleton, but how they take effect depends on Cambodia’s domestic transposition and the current position of the competent authority.

GRZAN note: the AMDD was signed by 10 member states and entered into force on 1 January 2015; its classification rules sit in Annex 2 (non-IVD) and Annex 3 (IVD); the technical document template is Annex 4; the post-market alert system is set out in Article 12.

2. Regulatory Basis

3. Expert Commentary

1. Being a “party” does not mean the provisions apply directly. The qualifying sentence in AMDD Article 22 is the key: the Directive is valid only among member states that have ratified or accepted it. When citing the AMDD in compliance documents, the accurate formulation is “the regional harmonisation obligations Cambodia has undertaken as a party to the AMDD”, never “under Article X of Cambodian law”. The legal consequences of the two formulations differ completely in a dispute.

1. The AMDD’s practical role in Cambodia is to fill the gaps in domestic provisions. Because the provisions of Prakas No. 1258 are not fully public, and the DDF’s device-side online guidance page still showed “coming soon” as of 15 October 2026, the AMDD has become the only set of technical requirements that is public, stable and searchable article by article. Preparing documentation to the AMDD is in effect using a regional standard to satisfy a market whose domestic provisions are opaque.

1. The three exceptions in Article 6 are often misread as “exemption channels”. The discretionary exemption in Article 6(2) and the special public health authorisation in paragraph 5 are both decided by the regulatory authority; they are not rights a company can claim on its own. The custom-made device exception in paragraph 4 is defined by the regulation and cannot be invoked simply by labelling the product accordingly. The prudent course in practice is to prepare on the basis that “registration is required”.

4. Practical Recommendations

1. Organise the technical dossier to the CSDT of AMDD Annex 4 and keep it consistent with the Thai, Malaysian, Singaporean and Indonesian versions. This yields two benefits: it meets Cambodia’s current review requirements, and once an ASEAN single submission model lands, the dossier can be reused directly.
2. Flag the hierarchy when citing the AMDD. In internal compliance documents and client communications, always write “AMDD Article X (regional harmonisation instrument; Cambodia is a party)” to avoid the text being misread as a provision of Cambodian domestic law.
3. Do not use Article 6 as the basis for skipping registration. Unless a written exemption or special authorisation has been obtained from the DDF, prepare for the full registration route. A business plan premised on an exemption that is later refused loses the entire market window.

5. Verification Checklist

• □ Confirmed the AMDD entered into force on 1 January 2015 and Cambodia is one of the signatories
• □ Understood the limitation in Article 22 that the Directive is “valid only among member states that have ratified or accepted it”
• □ Product classified under Annex 2 (non-IVD) or Annex 3 (IVD) with the basis documented
• □ Technical dossier organised to the seven modules of Annex 4 CSDT
• □ External documents citing the AMDD flagged as a “regional harmonisation instrument”
• □ No reliance on the Article 6 exemptions as a basis for skipping registration

Regulatory information verified as of 29 October 2026.

In Southeast Asia, GRZAN’s core capabilities concentrate on three areas. First, distinguishing the legislative progress of dedicated medical device laws across member states — Singapore, Malaysia, Thailand, Indonesia, the Philippines and Vietnam have each established a written device regulatory framework, whereas Cambodia still has no dedicated Medical Device Law; its current rules are assembled from three layers — the registration-number legal basis provided by the 1996 Law on the Management of Pharmaceuticals and its 2007 amendment, the classification and procedures provided by Prakas No. 1258 of 2012, and the technical framework provided by the ASEAN Medical Device Directive — leaving regulatory certainty materially lower than in markets that have completed legislation. Second, local authorised representative services: GRZAN can act as the manufacturer’s statutory representative in Cambodia, undertaking registration submissions, regulatory communication and post-market reporting obligations, and assisting with the practical implementation of the Cambodian registered pharmacist requirement and the pharmaceutical import and export enterprise licence. Third, quality system and testing support: helping establish a quality management system meeting ISO 13485 requirements and organising the technical dossier according to the ASEAN Common Submission Dossier Template (CSDT).

Business enquiries: info@grzanglobal.com